Global Next Generation Antibody Therapeutics Market - 2025 -2033
Next Generation Antibody Therapeutics Market Size
The global next generation antibody therapeutics market size reached US$ 9.09 Billion in 2024 from US$ 8.28 Billion in 2023 and is expected to reach US$ 22.88 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.
Overview
The next-generation antibody therapeutics market is driven by rising cancer prevalence, technological advances, and strong clinical pipelines. A notable trend is the shift toward subcutaneous delivery, improving patient convenience and reducing hospital load. The market is evolving rapidly, propelled by advanced modalities like ADCs, bispecific/multispecific constructs, Fc-engineered antibodies, and antibody-mimetic scaffolds, which enable enhanced specificity, dual-target engagement, and improved safety profiles. Key challenges include high development costs, complex manufacturing, and stringent regulatory oversight.
Dynamics
Drivers:
Investments, partnerships, and strategic deals are significantly driving the next generation antibody therapeutics market growth
Investments, partnerships, and strategic deals are playing a pivotal role in accelerating the growth of the next-generation antibody therapeutics market by pooling resources, sharing risks, and enabling faster innovation. The development of advanced modalities like antibody-drug conjugates (ADCs), bispecifics, and engineered Fc antibodies requires significant R&D funding and specialized know-how, which is increasingly achieved through collaborations between biotech innovators and large pharmaceutical companies.
For instance, in March 2025, Callio Therapeutics announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The company intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program.
Restraints:
Immunogenicity & safety concerns are hampering the growth of the next generation antibody therapeutics market
Immunogenicity and safety concerns remain significant hurdles hampering the growth of the next-generation antibody therapeutics market, as even advanced engineered antibodies can trigger unintended immune responses. Despite humanization and Fc-engineering efforts, some patients develop anti-drug antibodies (ADAs) that neutralize therapeutic effects or alter drug pharmacokinetics, leading to reduced efficacy or treatment discontinuation.
For instance, certain bispecific antibodies like blinatumomab have been associated with severe cytokine release syndrome (CRS) and neurotoxicity, requiring careful dose titration and hospital monitoring. Similarly, antibody-drug conjugates such as trastuzumab emtansine (Kadcyla) can cause off-target toxicities due to premature payload release. These risks increase regulatory scrutiny, with agencies demanding more extensive safety data and post-marketing surveillance, which can delay approvals and raise development costs.
Safety concerns also complicate patient recruitment in clinical trials, particularly for rare diseases where small sample sizes magnify adverse event risks. Moreover, market uptake can be hindered by physician hesitation in prescribing newer constructs without long-term safety profiles. Collectively, these immunogenicity and safety challenges slow market penetration and increase attrition rates, forcing developers to invest heavily in preclinical predictive models, biomarker-based patient selection, and safer linker-payload technologies to mitigate risks.
Segmentation Analysis
The global next generation antibody therapeutics market is segmented based on technology, therapeutic area, end-user, and region.
The oncology segment from the therapeutic area is dominating the next generation antibody therapeutics market with a 41.18% share in 2024
Next-gen formats such as antibody-drug conjugates (ADCs), bispecific antibodies, and checkpoint inhibitor-based combinations offer targeted mechanisms that can deliver potent cytotoxic payloads or redirect immune cells with high precision, minimizing damage to healthy tissue. For instance, in July 2025, Zymeworks Inc. announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company’s proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of hepatocellular carcinoma (HCC).
With multiple blockbuster antibodies already approved and hundreds in oncology-focused pipelines, pharma leaders like Roche, Pfizer, Bio-Thera Solutions, AstraZeneca, and Merck continue to prioritize oncology as the primary growth engine for next-generation antibody therapeutics. For instance, in June 2025, Bio-Thera Solutions Inc. announced that dosing had begun in a phase 3 clinical study for BAT8006, an antibody drug conjugate targeting folate receptor ? for the treatment of platinum-resistant ovarian cancer. The phase 3, randomized, open-label, parallel-group clinical trial of BAT8006 is designed to assess the efficacy of BAT8006 versus the investigator's choice of single-agent chemotherapy in patients with platinum-resistant high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Geographical Share Analysis
North America is expected to dominate the global next generation antibody therapeutics market with a 41.69% in 2024
North America dominates the global next-generation antibody therapeutics market due to its strong biotechnology ecosystem, advanced healthcare infrastructure, and high adoption of innovative biologics. The region, particularly the United States, hosts many of the world’s leading pharmaceutical and biotech companies, such as Pfizer, Amgen and Bio-Thera Solutions, which are actively developing next-gen modalities like antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered therapeutics.
The U.S. Food and Drug Administration (FDA) provides supportive regulatory frameworks, including Breakthrough Therapy and Orphan Drug designations, accelerating approvals for high-potential oncology and rare disease antibodies illustrated by the rapid clearance. For instance, in July 2025, Sutro Biopharma, Inc. announced that it entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF technology to precisely engineer ADCs with predefined attributes, as well as the FDA’s cutting-edge analytical capabilities to fully characterize these materials.
Competitive Landscape
Top companies in the next generation antibody therapeutics market include F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Biogen, ADC Therapeutics SA and Genmab A/S, among others.
The global next generation antibody therapeutics market report delivers a detailed analysis with 59 key tables, more than 58 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global next generation antibody therapeutics market size reached US$ 9.09 Billion in 2024 from US$ 8.28 Billion in 2023 and is expected to reach US$ 22.88 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.
Overview
The next-generation antibody therapeutics market is driven by rising cancer prevalence, technological advances, and strong clinical pipelines. A notable trend is the shift toward subcutaneous delivery, improving patient convenience and reducing hospital load. The market is evolving rapidly, propelled by advanced modalities like ADCs, bispecific/multispecific constructs, Fc-engineered antibodies, and antibody-mimetic scaffolds, which enable enhanced specificity, dual-target engagement, and improved safety profiles. Key challenges include high development costs, complex manufacturing, and stringent regulatory oversight.
Dynamics
Drivers:
Investments, partnerships, and strategic deals are significantly driving the next generation antibody therapeutics market growth
Investments, partnerships, and strategic deals are playing a pivotal role in accelerating the growth of the next-generation antibody therapeutics market by pooling resources, sharing risks, and enabling faster innovation. The development of advanced modalities like antibody-drug conjugates (ADCs), bispecifics, and engineered Fc antibodies requires significant R&D funding and specialized know-how, which is increasingly achieved through collaborations between biotech innovators and large pharmaceutical companies.
For instance, in March 2025, Callio Therapeutics announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The company intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program.
Restraints:
Immunogenicity & safety concerns are hampering the growth of the next generation antibody therapeutics market
Immunogenicity and safety concerns remain significant hurdles hampering the growth of the next-generation antibody therapeutics market, as even advanced engineered antibodies can trigger unintended immune responses. Despite humanization and Fc-engineering efforts, some patients develop anti-drug antibodies (ADAs) that neutralize therapeutic effects or alter drug pharmacokinetics, leading to reduced efficacy or treatment discontinuation.
For instance, certain bispecific antibodies like blinatumomab have been associated with severe cytokine release syndrome (CRS) and neurotoxicity, requiring careful dose titration and hospital monitoring. Similarly, antibody-drug conjugates such as trastuzumab emtansine (Kadcyla) can cause off-target toxicities due to premature payload release. These risks increase regulatory scrutiny, with agencies demanding more extensive safety data and post-marketing surveillance, which can delay approvals and raise development costs.
Safety concerns also complicate patient recruitment in clinical trials, particularly for rare diseases where small sample sizes magnify adverse event risks. Moreover, market uptake can be hindered by physician hesitation in prescribing newer constructs without long-term safety profiles. Collectively, these immunogenicity and safety challenges slow market penetration and increase attrition rates, forcing developers to invest heavily in preclinical predictive models, biomarker-based patient selection, and safer linker-payload technologies to mitigate risks.
Segmentation Analysis
The global next generation antibody therapeutics market is segmented based on technology, therapeutic area, end-user, and region.
The oncology segment from the therapeutic area is dominating the next generation antibody therapeutics market with a 41.18% share in 2024
Next-gen formats such as antibody-drug conjugates (ADCs), bispecific antibodies, and checkpoint inhibitor-based combinations offer targeted mechanisms that can deliver potent cytotoxic payloads or redirect immune cells with high precision, minimizing damage to healthy tissue. For instance, in July 2025, Zymeworks Inc. announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for ZW251, a novel glypican-3 (GPC3)-targeted ADC incorporating the company’s proprietary topoisomerase 1 inhibitor (TOPO1i) payload, ZD06519, for the treatment of hepatocellular carcinoma (HCC).
With multiple blockbuster antibodies already approved and hundreds in oncology-focused pipelines, pharma leaders like Roche, Pfizer, Bio-Thera Solutions, AstraZeneca, and Merck continue to prioritize oncology as the primary growth engine for next-generation antibody therapeutics. For instance, in June 2025, Bio-Thera Solutions Inc. announced that dosing had begun in a phase 3 clinical study for BAT8006, an antibody drug conjugate targeting folate receptor ? for the treatment of platinum-resistant ovarian cancer. The phase 3, randomized, open-label, parallel-group clinical trial of BAT8006 is designed to assess the efficacy of BAT8006 versus the investigator's choice of single-agent chemotherapy in patients with platinum-resistant high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Geographical Share Analysis
North America is expected to dominate the global next generation antibody therapeutics market with a 41.69% in 2024
North America dominates the global next-generation antibody therapeutics market due to its strong biotechnology ecosystem, advanced healthcare infrastructure, and high adoption of innovative biologics. The region, particularly the United States, hosts many of the world’s leading pharmaceutical and biotech companies, such as Pfizer, Amgen and Bio-Thera Solutions, which are actively developing next-gen modalities like antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered therapeutics.
The U.S. Food and Drug Administration (FDA) provides supportive regulatory frameworks, including Breakthrough Therapy and Orphan Drug designations, accelerating approvals for high-potential oncology and rare disease antibodies illustrated by the rapid clearance. For instance, in July 2025, Sutro Biopharma, Inc. announced that it entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF technology to precisely engineer ADCs with predefined attributes, as well as the FDA’s cutting-edge analytical capabilities to fully characterize these materials.
Competitive Landscape
Top companies in the next generation antibody therapeutics market include F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Biogen, ADC Therapeutics SA and Genmab A/S, among others.
The global next generation antibody therapeutics market report delivers a detailed analysis with 59 key tables, more than 58 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Technology
2.4. Snippet by Therapeutic Area
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expansion into Autoimmune & Rare Disease Areas
3.1.1.2. Investments, Partnerships, and Strategic Deals
3.1.2. Restraints
3.1.2.1. Manufacturing Complexity & Conjugation Challenges
3.1.2.2. Immunogenicity & Safety Concerns
3.1.3. Opportunity
3.1.3.1. Rapid Innovation via Nanobodies & Antibody Fragments
3.1.3.2. Personalized & Biomarker-Driven Precision Medicine
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY TECHNOLOGY
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
5.1.2. Market Attractiveness Index, By Technology
5.2. Antibody-Drug Conjugates (ADCs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Bispecific Antibodies
5.4. Fc-engineered / Fc-fusion & Half-Life Extension
5.5. Antibody Fragments & Scaffolds
5.6. Others
6. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune & Inflammatory Diseases
6.4. Infectious Diseases
6.5. Ophthalmology
6.6. Rare Diseases
6.7. Others
7. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Ambulatory Surgical Centers
7.5. Academic and Research Institutes
7.6. Others
8. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9. INTRODUCTION
9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd*
12.1.1. Company Overview
12.1.1.1. Product Portfolio
12.1.1.2. Product Description
12.1.1.3. Product Key Performance Indicators (KPIs)
12.1.2. Financial Overview
12.1.2.1. Company Revenue
12.1.2.2. Geographical Revenue Shares
12.1.2.3. Revenue Forecasts
12.1.3. Key Developments
12.1.3.1. Mergers & Acquisitions
12.1.3.2. Key Product Development Activities
12.1.3.3. Regulatory Approvals, etc.
12.1.3.4. SWOT Analysis
12.2. Amgen Inc.
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. AstraZeneca
12.6. Merck & Co., Inc.
12.7. Biogen
12.8. ADC Therapeutics SA
12.9. Genmab A/S (LIST NOT EXHAUSTIVE )
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Technology
2.4. Snippet by Therapeutic Area
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Expansion into Autoimmune & Rare Disease Areas
3.1.1.2. Investments, Partnerships, and Strategic Deals
3.1.2. Restraints
3.1.2.1. Manufacturing Complexity & Conjugation Challenges
3.1.2.2. Immunogenicity & Safety Concerns
3.1.3. Opportunity
3.1.3.1. Rapid Innovation via Nanobodies & Antibody Fragments
3.1.3.2. Personalized & Biomarker-Driven Precision Medicine
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. SWOT Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics
5. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY TECHNOLOGY
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
5.1.2. Market Attractiveness Index, By Technology
5.2. Antibody-Drug Conjugates (ADCs)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Bispecific Antibodies
5.4. Fc-engineered / Fc-fusion & Half-Life Extension
5.5. Antibody Fragments & Scaffolds
5.6. Others
6. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune & Inflammatory Diseases
6.4. Infectious Diseases
6.5. Ophthalmology
6.6. Rare Diseases
6.7. Others
7. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Ambulatory Surgical Centers
7.5. Academic and Research Institutes
7.6. Others
8. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9. INTRODUCTION
9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.1. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. China
9.4.6.2. India
9.4.6.3. Japan
9.4.6.4. South Korea
9.4.6.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Brazil
9.5.6.2. Argentina
9.5.6.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
11.1. Market Share Analysis and Positioning Matrix
11.2. Strategic Partnerships, Mergers & Acquisitions
11.3. Key Developments in Product Portfolios and Innovations
11.4. Company Benchmarking
12. COMPANY PROFILES
12.1. F. Hoffmann-La Roche Ltd*
12.1.1. Company Overview
12.1.1.1. Product Portfolio
12.1.1.2. Product Description
12.1.1.3. Product Key Performance Indicators (KPIs)
12.1.2. Financial Overview
12.1.2.1. Company Revenue
12.1.2.2. Geographical Revenue Shares
12.1.2.3. Revenue Forecasts
12.1.3. Key Developments
12.1.3.1. Mergers & Acquisitions
12.1.3.2. Key Product Development Activities
12.1.3.3. Regulatory Approvals, etc.
12.1.3.4. SWOT Analysis
12.2. Amgen Inc.
12.3. Bristol-Myers Squibb Company
12.4. Pfizer Inc.
12.5. AstraZeneca
12.6. Merck & Co., Inc.
12.7. Biogen
12.8. ADC Therapeutics SA
12.9. Genmab A/S (LIST NOT EXHAUSTIVE )
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Next Generation Antibody Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 7 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 9 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Next Generation Antibody Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Next Generation Antibody Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 14 North America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 15 North America Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 Europe Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 19 Europe Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 26 South America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 27 South America Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 F. Hoffmann-La Roche Ltd: Overview
Table 34 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 35 F. Hoffmann-La Roche Ltd: Key Developments
Table 36 Amgen Inc.: Overview
Table 37 Amgen Inc.: Product Portfolio
Table 38 Amgen Inc.: Key Developments
Table 39 Bristol-Myers Squibb Company: Overview
Table 40 Bristol-Myers Squibb Company: Product Portfolio
Table 41 Bristol-Myers Squibb Company: Key Developments
Table 42 Pfizer Inc.: Overview
Table 43 Pfizer Inc.: Product Portfolio
Table 44 Pfizer Inc.: Key Developments
Table 45 AstraZeneca: Overview
Table 46 AstraZeneca: Product Portfolio
Table 47 AstraZeneca: Key Developments
Table 48 Merck & Co., Inc.: Overview
Table 49 Merck & Co., Inc.: Product Portfolio
Table 50 Merck & Co., Inc.: Key Developments
Table 51 Biogen: Overview
Table 52 Biogen: Product Portfolio
Table 53 Biogen: Key Developments
Table 54 ADC Therapeutics SA: Overview
Table 55 ADC Therapeutics SA: Product Portfolio
Table 56 ADC Therapeutics SA: Key Developments
Table 57 Genmab A/S: Overview
Table 58 Genmab A/S: Product Portfolio
Table 59 Genmab A/S: Key Developments
Table 1 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Next Generation Antibody Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 7 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 9 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Next Generation Antibody Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Next Generation Antibody Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 14 North America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 15 North America Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 Europe Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 19 Europe Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 26 South America Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 27 South America Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Technology, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Therapeutic Area, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Next Generation Antibody Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 F. Hoffmann-La Roche Ltd: Overview
Table 34 F. Hoffmann-La Roche Ltd: Product Portfolio
Table 35 F. Hoffmann-La Roche Ltd: Key Developments
Table 36 Amgen Inc.: Overview
Table 37 Amgen Inc.: Product Portfolio
Table 38 Amgen Inc.: Key Developments
Table 39 Bristol-Myers Squibb Company: Overview
Table 40 Bristol-Myers Squibb Company: Product Portfolio
Table 41 Bristol-Myers Squibb Company: Key Developments
Table 42 Pfizer Inc.: Overview
Table 43 Pfizer Inc.: Product Portfolio
Table 44 Pfizer Inc.: Key Developments
Table 45 AstraZeneca: Overview
Table 46 AstraZeneca: Product Portfolio
Table 47 AstraZeneca: Key Developments
Table 48 Merck & Co., Inc.: Overview
Table 49 Merck & Co., Inc.: Product Portfolio
Table 50 Merck & Co., Inc.: Key Developments
Table 51 Biogen: Overview
Table 52 Biogen: Product Portfolio
Table 53 Biogen: Key Developments
Table 54 ADC Therapeutics SA: Overview
Table 55 ADC Therapeutics SA: Product Portfolio
Table 56 ADC Therapeutics SA: Key Developments
Table 57 Genmab A/S: Overview
Table 58 Genmab A/S: Product Portfolio
Table 59 Genmab A/S: Key Developments
LIST OF FIGURES
Figure 1 Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 3 Global Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 4 Global Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Next Generation Antibody Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 7 Antibody-Drug Conjugates (ADCs) Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Bispecific Antibodies Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Fc-engineered / Fc-fusion & Half-Life Extension Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Antibody Fragments & Scaffolds Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Others Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Therapeutic Area, 2023-2033 (%)
Figure 13 Oncology Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Autoimmune & Inflammatory Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Infectious Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Ophthalmology Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Rare Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 20 Hospitals End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Specialty Clinics End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Ambulatory Surgical Centers End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic and Research Institutes End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Others End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 28 North America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 29 North America Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 30 North America Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 33 Europe Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 34 Europe Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Europe Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 38 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 39 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 43 South America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 44 South America Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 45 South America Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 48 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 49 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 50 F. Hoffmann-La Roche Ltd: Financials
Figure 51 Amgen Inc.: Financials
Figure 52 Bristol-Myers Squibb Company: Financials
Figure 53 Pfizer Inc.: Financials
Figure 54 AstraZeneca: Financials
Figure 55 Merck & Co., Inc.: Financials
Figure 56 Biogen: Financials
Figure 57 ADC Therapeutics SA: Financials
Figure 58 Genmab A/S: Financials
Figure 1 Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 3 Global Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 4 Global Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Next Generation Antibody Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 7 Antibody-Drug Conjugates (ADCs) Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 8 Bispecific Antibodies Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Fc-engineered / Fc-fusion & Half-Life Extension Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Antibody Fragments & Scaffolds Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Others Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Therapeutic Area, 2023-2033 (%)
Figure 13 Oncology Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 14 Autoimmune & Inflammatory Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Infectious Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Ophthalmology Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Rare Diseases Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Therapeutic Area in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 20 Hospitals End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Specialty Clinics End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Ambulatory Surgical Centers End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic and Research Institutes End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Others End-User in Global Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Next Generation Antibody Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 28 North America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 29 North America Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 30 North America Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 33 Europe Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 34 Europe Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Europe Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 38 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 39 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 40 Asia-Pacific Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 41 South America Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 42 South America Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 43 South America Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 44 South America Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 45 South America Next Generation Antibody Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Middle East and Africa Next Generation Antibody Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By Technology, 2024 & 2033 (%)
Figure 48 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By Therapeutic Area, 2024 & 2033 (%)
Figure 49 Middle East and Africa Next Generation Antibody Therapeutics Market Share, By End-User, 2024 & 2033 (%)
Figure 50 F. Hoffmann-La Roche Ltd: Financials
Figure 51 Amgen Inc.: Financials
Figure 52 Bristol-Myers Squibb Company: Financials
Figure 53 Pfizer Inc.: Financials
Figure 54 AstraZeneca: Financials
Figure 55 Merck & Co., Inc.: Financials
Figure 56 Biogen: Financials
Figure 57 ADC Therapeutics SA: Financials
Figure 58 Genmab A/S: Financials
